17 December 2025

Topadur Appoints Matthias Schäfer as Chief Executive Officer to Lead Next Phase of Company Growth

• Founder and President of the Board Dr. Reto Naef assumes the role of Senior Scientific Advisor, continuing to support the company’s scientific direction
• Company enters next phase of clinical advancement with programs progressing toward strategic milestones

Zurich, Switzerland – Topadur Pharma AG, a clinical-stage biotechnology company developing innovative therapies for vascular regeneration, today announced the appointment of PD Dr. Matthias Schäfer as Chief Executive Officer.

Dr. Schäfer joined Topadur in 2024 as Chief Innovation Officer and Deputy CEO and now assumes executive leadership as the company advances its pipeline into the next stages of clinical development toward commercialization.

Founder Dr. Reto Naef remains on the leadership team as Senior Scientific Advisor and continues to guide the company’s strategy as President of the Board, ensuring continuity in Topadur’s long-term growth.

Matthias Schäfer brings more than 20 years of experience across the life sciences and healthcare sectors. He has directed research and clinical development programs, driven global portfolio expansion, and established strategic partnerships across diverse therapeutic areas. Dr. Schäfer has held senior leadership roles including at Geistlich Pharma AG and pfm medical GmbH, where he translated scientific innovation into sustainable commercial growth and strengthened global market presence. He received a PhD in Biology from the University of Würzburg and completed his habilitation at ETH Zurich.

“Topadur is entering an important phase as we advance toward meaningful clinical milestones,” said Dr. Schäfer. “Our priorities are progressing our lead programs in the clinical phases, increasing liquidity, and strengthening the organizational capabilities and partnerships needed to support continued growth. I look forward to working closely with our outstanding team to build on this momentum and advance our programs through their upcoming inflection points.”

“As a scientist and entrepreneur, I founded Topadur with the conviction that vascular regeneration has the power to treat a variety of aging-related diseases,” said Dr. Naef. “Today, the company stands on a strong scientific and clinical foundation. With Matthias stepping into the CEO role, we are ready to accelerate momentum and advance our programs into the next stage. I look forward to continuing to help shape Topadur’s strategic and scientific direction as President of the Board and in my new role as Senior Scientific Advisor.”

 
Advancing the Technology Platform and Clinical Pipeline

Topadur’s DualTOP^® platform is designed to restore healthy microcirculation and support tissue regeneration across multiple therapeutic areas.

The company’s lead asset, TOP-N53, is in Phase 2a clinical development for treatment of digital ulcers in patients with systemic sclerosis and has received Orphan Drug Designation from both the FDA and EMA. Supported by positive clinical Phase 1 data, TOP-N53 is also being advanced for development in diabetic foot ulcers, a major global health challenge and area of significant unmet clinical need, with one diabetes-related amputation occurring every 20 seconds[i].

Topadur’s second lead asset, TOP-M119, targeting androgenetic and chemotherapy-induced alopecia, is completing toxicology studies ahead of planned clinical entry. Building on the regenerative potential of the DualTOP^® platform, Topadur is also prioritizing innovative applications in skin rejuvenation and longevity, areas with rapidly growing scientific and commercial relevance. Complementary exploratory investigations are underway in oncology and other indications.

About Topadur
Topadur Pharma AG is a Swiss clinical-stage biotechnology company developing first-in-class therapies that restore microvascular function and reactivate tissue regeneration. Founded in 2015, the company focuses on diseases where impaired local blood flow is a key driver of tissue degeneration, impaired repair processes, and progression of chronic conditions with aging.

Topadur’s proprietary DualTOP^® platform targets the signaling cascade of cGMP, a central regulator of blood vessel function and tissue repair, through a dual mechanism designed to improve microcirculation directly at the site of disease. The company is advancing a pipeline of first-in-class candidates in high-need indications, supported by a capital-efficient, partnership-driven R&D model and a global network of scientific collaborators.

Beyond these lead indications, Topadur is pursuing focused preclinical programs in conditions where improved microcirculation may offer therapeutic benefit.

For more information, please visit: www.topadur.com

Contact
Topadur Pharma AG
Yoshita Bhide
Media Communications
+41 44 755 44 66
yoshita.bhide@topadur.com

Disclaimer
This communication does not constitute an offer or invitation to subscribe for or purchase any securities of Topadur Pharma AG. This publication may contain certain forward-looking statements and assessments or intentions concerning the company and its business. Such statements involve certain risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of the company to be materially different from those expressed or implied by such statements. Readers should therefore not place reliance on these statements, particularly not in connection with any contract or investment decision. The company disclaims any obligation to update these forward-looking statements, assessments or intentions.

^[i] Armstrong DG, Boulton AJM, and Bus SA (2017): Diabetic Foot Ulcers and Their Recurrence.
New England Journal of Medicine, 376(24):2367–2375.

MRM Health Enters Strategic Collaboration with Oncode Institute and the Netherlands Cancer Institute to Accelerate Program on Microbiome-Based Therapies that Enhance Cancer Immunotherapy 

• R&D partnership combines the cutting-edge microbiome science of MRM Health with leading translational research and clinical expertise of Prof. Emile Voest’s research group at the NKI to create next-generation immune-oncology therapies
• Program will leverage MRM Health’s proprietary CORAL® platform to develop live biotherapeutic products to improve the efficacy of immune checkpoint inhibitors

Ghent, Belgium and Amsterdam, The Netherlands – December 17, 2025 – MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the company has entered into a strategic collaboration with the research group of Prof. Emile Voest, Senior Group Leader at the Netherlands Cancer Institute (NKI) and Senior Investigator at Oncode Institute. Prof. Voest has established strong expertise in tumor microbiome research, including its role in cancer progression and treatment response, as well as in the integration of real-world clinical data to inform translational oncology. Through this collaboration, MRM Health aims to accelerate the development of novel live biotherapeutic products (LBPs) to improve the efficacy of immune checkpoint inhibitors (ICIs) in cancer treatment.

ICIs have transformed cancer therapy but are limited by immune-related adverse events (irAEs), heightened toxicity in combinations, primary or acquired resistance in many patients, and chronic effects impairing quality of life. Growing scientific evidence demonstrates that the gut microbiome can have a positive impact on these resistance mechanisms and irAEs, offering the potential to enhance ICI efficacy, safety, and combination potential through targeted modulation. Specific microbiome compositions and functions are associated with more favorable clinical outcomes. On the other hand, microbiome dysbiosis or imbalance, induced by, for example, antibiotics or other therapies, has been linked to reduced survival. Methods aiming to alter the microbiome show promise in improving immunotherapy responses across preclinical and early clinical research.

Innovative bacterial consortia designed to boost cancer immunotherapy 

MRM Health is applying its proprietary CORAL® platform to design and develop optimized bacterial consortia that can restore the dysbiotic microbiome while modulating immune and metabolic pathways relevant to ICI response. The close partnership with Prof. Voest, will provide unique insights into patient disease profiles, advanced microbiome data and immune cell profiling, which should enable the acceleration of MRM Health’s internal program.

“We are entering a new era where the microbiome will become a key driver of immunotherapy success,” said Sam Possemiers, CEO of MRM Health. “By combining our rational microbiome design platform with the deep oncology and immunology expertise of Prof. Voest and his team at the NKI, we aim to accelerate the creation of next-generation therapies that increase response rates to immune checkpoint inhibitors, meaningfully improving patient outcomes across multiple cancer types. This collaboration also positions MRM Health in one of the fastest-growing segments of the global cancer market, reinforcing our leadership in microbiome-driven innovation with the objective of developing best-in-class live biotherapeutic products in this field.”

“Our research has demonstrated the critical role of the gut microbiome and its metabolites in shaping responses to immunotherapy,” noted Prof. Emile Voest, Professor of Medical Oncology at the University Medical Center Utrecht and Senior Group Leader at the Netherlands Cancer Institute (NKI). “By partnering with MRM Health, which is at the forefront of this technology, our insights can be turned into innovative therapeutic strategies aimed at overcoming resistance and unlocking the full potential of ICI treatments.”

“Our collaboration with MRM Health exemplifies Oncode Institute’s mission to turn important academic discoveries into tangible patient and economic benefits,” says Bertholt Leeftink, Managing Director of Oncode Institute. “This public–private collaboration underscores that world-class research and a strong, innovative biotech industry are essential to delivering new and more effective treatments for patients, while also creating new business opportunities.”

***

About the CORAL® platform

MRM Health’s CORAL® platform is a technology for creating and manufacturing next-generation live biotherapeutic products (LBPs) based on optimized bacteria consortia. CORAL® uses a bioinformatics-guided discovery engine to identify therapeutic strains and a proprietary optimization technology to create consortia with faster onset-of-action and increased potency. The platform’s key differentiator is its manufacturing process, which produces the entire consortia as a single drug substance, allowing for scalable, cost-effective, and standardized production.

About MRM Health

MRM Health is a clinical-stage biotech developing innovative microbiome-based Live Biotherapeutic Products for chronic inflammatory diseases with high unmet need. Its CORAL® platform enables the design and manufacturing of disease-focused microbial consortia with enhanced efficacy and scalability. In addition to advancing its lead program MH002 into pivotal clinical development in ulcerative colitis and the orphan disease indication pouchitis, MRM Health has ongoing preclinical programs in other inflammatory diseases and in immune-oncology.

For more information, please follow us on LinkedIn or visit the website at www.mrmhealth.com.

About Prof. Emile Voest

Emile Voest is professor of Medical Oncology, Senior Group Leader at the Netherlands Cancer Institute, Senior Scientist of the Oncode Institute, and translational scientist. Until 2021, he served as executive medical director of the Netherlands Cancer Institute. In addition, he is an independent, non-executive board member of Sanofi and is co-founder and non-executive board member of the Hartwig Medical Foundation. He also co-founded Mosaic Therapeutics, devoted to developing new combinatorial treatments in a specific genomic background. His academic group is devoted to bringing precision medicine to patients and focuses on the development of genomics and immune-guided treatment strategies by employing sophisticated co-culture models, computational approaches and clinical trials to improve drug development and immunotherapy. 

About Oncode Institute

Oncode Institute is a Dutch cancer research and innovation organization dedicated to accelerating breakthroughs in cancer research and translating them into impactful diagnostics and treatments. We bring together 62 leading researchers and their teams from 13 partner institutes to pursue cutting-edge, high-risk, high-gain research. Through an integrated approach that bridges discovery, clinical practice, and market needs, Oncode Institute drives the transformation of innovations into tangible benefits for patients. We foster collaboration and drive valorization to maximize impact – advancing science, improving health outcomes, and contributing to economic value. Founded on the pillars of science, collaboration, and valorization, Oncode Institute is committed to outsmarting cancer and impacting lives. www.oncodeinstitute.nl

About NKI

The Netherlands Cancer Institute, founded in 1913, is among the top 10 comprehensive cancer centers, combining world-class fundamental, translational, and clinical research with dedicated patient care. Our initiatives to promote excellent translational research have been recognized by the European Academy of Cancer Sciences, when they designated us ‘Comprehensive Cancer Center of Excellence in Translational Research’.

Contacts:
 

Düsseldorf, 16 December 2025 – The European medical cannabis and industrial hemp group SYNBIOTIC SE (ISIN: DE000A3E5A59 | WKN: A3E5A5) announces a strategic equity investment. The specialised cannabis and hemp equity fund CANSOUL – Hanf Aktien Global (WKN: A2PX8U | ISIN: LI0514446843) has acquired a stake in SYNBIOTIC as part of a cash capital increase.

CANSOUL is a specialised equity fund investing across the entire global value chain of the hemp and cannabis industry. Its holistic investment approach covers cultivation, research, technology, extraction and distribution through to pharmaceutical development. The fund invests globally in leading industry players and diversifies across medical cannabis, industrial hemp, CBD and — in legally regulated jurisdictions — the recreational market. CANSOUL’s objective is to identify early-stage trends in infrastructure, patents and licences that fundamentally drive long-term market development.

Daniel Stehr, Founder of the CANSOUL Fund, commented: “Our decision to participate in the capital increase of SYNBIOTIC is based on an attractive fundamental valuation and the successful internal restructuring of the Group. SYNBIOTIC holds assets with strong strategic differentiation, including an import licence and GMP manufacturing authorisation for medical cannabis, as well as its shareholding in GOC Nexus with its patented cold plasma process for GMP sterilisation — a clear technological advantage in quality enhancement. Combined with market leadership in industrial hemp and a management team with deep regulatory expertise, SYNBIOTIC offers an attractive risk-return profile.”

The transaction marks the starting point of a long-term partnership. As one of the leading players in regulated cannabis investments, CANSOUL underscores the attractiveness of SYNBIOTIC’s diversified business model.

“The investment via the capital increase represents the beginning of a strategic engagement. The SYNBIOTIC position is now being built within the CANSOUL fund’s portfolio and is explicitly designed as a long-term investment to accompany the growth potential of the diversified platform over the coming years,” Stehr added.

Daniel Stehr and Daniel Kruse, CEO of SYNBIOTIC, jointly stated: “Germany is facing significant developments in the growth markets of cannabis and industrial hemp. However, those expecting a rapid ‘coffee shop boom’ are likely to be disappointed. We realistically see commercial recreational use materialising only over the next five to ten years. The near-term growth drivers lie in medical cannabis and industrial hemp — sectors that will expand substantially for healthcare and environmental policy reasons.”

Active on Intercontinental Capital Markets and at the Political Level

CANSOUL’s investment also reflects SYNBIOTIC’s increased visibility at key intercontinental capital market events.

At a Talman House event in London, Daniel Kruse and Patrick Hirschauer, from SYNBIOTIC’s management team, met numerous international investors and industry representatives. According to Hirschauer, sentiment was “exceptionally optimistic, with sustained and growing interest in the European cannabis market.”

At the German Equity Forum in Frankfurt, Supervisory Board member Dr Andreas Wuzik and Hirschauer presented SYNBIOTIC to a broad institutional audience. “Frankfurt felt like ‘Dragons’ Den’ — but with institutional investors,” Hirschauer noted. “The questions were critical, highly professional and very constructive. It was extremely valuable for us, as we were able to position SYNBIOTIC beyond sector-specific filters and further sharpen our business model in an industrial context.”

Daniel Kruse, CEO of SYNBIOTIC, participated in the inaugural meeting of the Foreign Trade Working Group on 26 November 2025 in Berlin with Federal Minister for Economic Affairs Reiche. He commented positively: “The meeting demonstrated that Germany’s domestic and foreign economic challenges are being recognised and that promising solutions — including new growth markets — are on the agenda. I am already looking forward to the next round of discussions.”

Publisher
SYNBIOTIC SE
Daniel Kruse
CEO
Münsterstraße 336
40470 Düsseldorf
Germany
www.synbiotic.com

Media
Rüdiger Tillmann
SYNBIOTIC Public Relations Manager
Email ruediger.tillmann@synbiotic.com
Mobile +49 170 9651451
c/o JOLE.group

About SYNBIOTIC
SYNBIOTIC is a listed group of companies in the medical cannabis and industrial hemp sector with a buy-and-build investment strategy focussed on Europe. The Group covers the entire value chain from cultivation to production and retail – from the field to shelf. The subsidiaries’ core businesses are research and development, production and the commercialisation of medical cannabis, industrial hemp and CBD products. SYNBIOTIC is pursuing a clear pan-European strategy of further expanding its business areas in order to cover the relevant growth markets while minimising risks and increasing opportunities for investors through diversification.

Ad hoc announcement

Vitruvia Medical AG

December 15, 2025

Vitruvia Medical AG successfully completes capital increase and strengthens its financial structure

Vitruvia Medical AG announces that a capital increase was successfully completed on December 15, 2025. The newly created capital was used in full to repay the convertible bond due at the beginning of December.

This measure strengthened the company’s equity and significantly reduced its debt. The improved capital structure secures the long-term financing of Vitruvia Medical AG and contributes significantly to the company’s economic stability.

The Board of Directors of Vitruvia AG

Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics

GENEVA (Dec. 15, 2025) – MindMaze Therapeutics Holding SA (SIX: MMTX) (MindMaze Therapeutics or the Company) announced today the completion of its business combination with NeuroX Group SA (NeuroX), a commercial-stage company delivering evidence-based, precision digital treatments for neurological diseases. The newly combined entity now operates under the name MindMaze Therapeutics Holding SA.

The closing follows the signing of a definitive business combination agreement in October 2025 and subsequent shareholder approval at the Company’s extraordinary general meeting in November. The transaction establishes a fully integrated company with a first-of-its-kind ecosystem, uniting precision digital neurotherapeutics, pharmacological treatments, cutting-edge devices, data, and an AI-powered platform, positioned to redefine neurological care and change patient lives.

“Neurological diseases are one of the leading causes of disability globally,” said Olaf Blanke (MD), member of the Board of Directors, Professor of Neuroscience and Cognitive Neuroprosthetics at the Swiss Federal Institute of Technology (EPFL) and Adjunct Professor at the Department of Clinical Neurosciences at the University Hospital of Geneva. “The situation is worsening due to aging populations, with 1 in 6 people expected to develop a neurological disease, making the need for effective, scalable solutions more urgent than ever. While neuro-rehabilitation requires intensive, repetitive training for functional recovery, traditional healthcare systems often fail to deliver adequate therapy, leaving millions of patients without optimal treatment. MindMaze Therapeutics seeks to address this gap by providing clinically proven neurotherapeutics to support their recovery journey, from hospital to rehab center to their home.”

“Today begins a new chapter for MindMaze Therapeutics,” commented Walid Hanna, Chairman of the Board of Directors of MindMaze Therapeutics. “The company is founded on clinically validated innovation, and driven by a mission to transform neurological care, addressing a critical and persistent gap in motor and cognition restorations in neurological conditions. We are now focused on advancing our precision neurotherapeutics platform to deliver impact at scale. Relief’s complementary capabilities and biopharmaceutical assets strengthen our growth strategy, supporting both drug-digital integration and expanding development opportunities.”

MindMaze Therapeutics acquired NeuroX through a share exchange in which all outstanding shares of NeuroX were contributed by its former shareholders in exchange for 140,000,000 newly issued ordinary shares of the Company. These new shares will be admitted to trading and listing on the SIX Swiss Exchange today, in accordance with the approved prospectus and applicable regulations. Effective immediately, all listed ordinary shares of the Company will trade under the updated ticker symbol MMTX. Following the transaction, the total number of outstanding shares amounts to 152,602,044, excluding treasury shares.
 

ABOUT MINDMAZE THERAPEUTICS
MindMaze Therapeutics is a Swiss-based, commercial-stage company formed in December 2025 through the business combination of RELIEF THERAPEUTICS Holding SA (Relief) and NeuroX Group SA. The Company develops and commercializes first-of-its-kind digital treatments for neurological diseases and brain disorders. Built on an advanced brain technology platform integrating software, sensors, and telehealth, its solutions are deployed globally across clinics and home settings. MindMaze Therapeutics’ clinically validated neurotherapeutics have demonstrated significant medico-economic outcomes across conditions such as stroke, Parkinson’s disease, and at-risk aging. The Company continues to expand its R&D pipeline into adjacent neurological indications, including multiple sclerosis, spinal cord injury, traumatic brain injury, and Alzheimer’s disease.

The Company also manages Relief’s preexisting portfolio of clinical and commercial biopharmaceutical assets focused on rare dermatological, metabolic, and respiratory diseases.

MindMaze Therapeutics is listed on the SIX Swiss Exchange under the ticker MMTX and quoted in the U.S. on OTCQB under RLFTF and RLFTY.

For more information, visit www.mindmazetherapeutics.com.
 

CONTACT
MindMaze Therapeutics Holding SA
Jeremy Meinen
Chief Financial Officer
ir@mindmaze.com
 

DISCLAIMER
This press release contains forward-looking statements, which may be identified by words such as “believe,” “assume,” “expect,” “intend,” “may,” “could,” “will,” or similar expressions. These statements are based on current plans and assumptions and are subject to risks and uncertainties that could cause actual results, financial condition, performance, or achievements to differ materially from those expressed or implied. Such factors include, among others, business, economic, financial, regulatory, and competitive factors, as well as the Company’s ability to execute its strategy and secure sufficient resources to support its operations. This communication is provided as of the date hereof, and MindMaze Therapeutics undertakes no obligation to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

Biotech Showcase™ 2026 Returns to San Francisco During JPM Week as a Premier Destination for Dealmakers

Partnering Platform Now Open for Registration

SAN FRANCISCO — December 12, 2025 — Biotech Showcase™ returns to San Francisco during J.P. Morgan Healthcare Week, marking its 19^th year as a premier destination for global biopharma leaders to showcase their companies and technologies, build relationships, and make deals with venture investors and partners. Taking place January 12-14 and virtually January 21-22, the event will gather more than 1,200 life sciences investors and 3,200 global biopharma professionals, including representatives from companies including PhRMA, BIO, Novo, Ipsen, Regeneron, and Sofinnova Investments.

Attendees can participate in one-to-one meetings with investors, partners and news media, provide corporate presentations, and engage in multiple face-to-face networking sessions. This year’s event will again seamlessly integrate with the TechBio and Seed Showcases, offering unmatched opportunities for investors and partners to engage with companies across the full spectrum of life science innovation. Virtual attendees will benefit from partnering privileges in addition to on-demand access to company showcases and session recordings. Access to extensive on-demand programming, including recordings of sessions and workshops is provided to all attendees.

“Reflecting the significant uptick in M&A and funding across the life sciences ecosystem, Biotech Showcase is set to deliver a record-breaking year in terms of networking and deal-making opportunities,” said Sara Jane Demy, Founder and CEO of Demy-Colton. “This year we’re anticipating more than 300 presenting companies, 1,200 investors and a projected 6,000+ one-to-one meetings, making Biotech Showcase the largest and most influential investor conference for private, micro-cap and mid-cap biotechnology companies, as well as TechBio companies, venture investors, and partnering companies.”

The 2026 agenda will feature discussions on trending topics, including:

• Strategic Adaptation to the New Policy Landscape
• Opportunities in Asia & Europe
• The Pharma Perspective
• The Future of Healthcare Access & Equity
• The Outlook for Biopharma Financing
• AI & Quantum Computing in Healthcare
• Investment in Women’s Health

“With a robust agenda focused on key industry trends in biopharma, and a lineup of exceptional company presentations from both public and private companies, Biotech Showcase has proven itself as the leading platform for connecting innovators and investors across the global biotech community,” Tina Elder, Global Managing Director, EBD Group US, added. “Many thanks to all our investors, speakers, sponsors, media and other attendees for enabling these important conversations that help drive the industry’s funding, collaboration and therapeutic breakthroughs.”

To register for Biotech Showcase or to apply to present or sponsor, please visit https://informaconnect.com/biotech-showcase/.

About Demy-Colton

Demy-Colton is a leading life sciences and digital health events organization at the forefront of building networks between innovative life sciences companies and industry stakeholders. Its unique events facilitate networking on a global scale, including Biotech Showcase™, BioFuture™, Global Biotech CEO Summit™, Executive Clinics™, and Demy-Colton Virtual Salons™. These events build networking communities that transcend geographical boundaries and establish ongoing, high-value relationships among the industry’s top decision-makers, investors and thought leaders. For more information, visit www.demy-colton.com. 

About Life Sciences Partnering and Investment by Informa

Our mission is to help collaborations get started across the life science value chain. Our range of partnering conferences has grown to become the largest and most productive conference platform in the industry. Each one of our landmark events held in key life science markets around the world is powered by our state-of-the-art partnering software, partneringONE®, that enables delegates to efficiently identify and engage with new opportunities via one-to-one meetings. Today our events (BIO-Europe®, BIO-Europe Spring®, Biotech Showcase™, ChinaBio® Partnering Forum, Asia Bio Partnering Forum, BioEquity Europe, LSX USA Congress, Investival Showcase Europe, European Lifestars Awards, Investival Showcase USA, LSX Europe Congress, LSX Nordic Congress) annually attract more than 14,000 senior life science executives who engage in over 83,000 one-to-one partnering meetings. These vital one-to-one engagements are the wellspring of deals that drive innovation in our industry.

Contacts

Katie Morris, PhD
ENTENTE Network of Companies
katiemorris@ententeinc.com

MC Services, Inc.
Laurie Doyle
Phone: +1-339-832-0752
E-mail: EBDGroup@mc-services.eu

Media release

PolyPeptide and Lupin Manufacturing Solutions Form Strategic Alliance to Meet Growing Demand for Peptide Supply in Metabolic Therapies

Baar, 12 December 2025 – PolyPeptide Group AG (SIX: PPGN), a global CDMO for peptide-based APIs, and Lupin Manufacturing Solutions Limited (LMS) have formed a strategic alliance to enhance supply chain resilience, improve operational efficiency, and support the long-term growth of both organizations.

Through this alliance, PolyPeptide will broaden its sourcing options for key materials, establishing a more robust and flexible supply chain for peptide manufacturing. The agreement sets a framework for long-term cooperation, including integrated procurement and supply planning for select raw materials. Both companies are committed to maintaining high standards of quality, reliability, and compliance.

“Reliability is a competitive advantage in our industry. Working with Lupin Manufacturing Solutions gives us the flexibility and supply chain depth needed to support growing customer demand, including metabolics demand,” said Dr. Stéphane Varray, Chief Commercial Officer, PolyPeptide. “When you’re enabling life-changing therapies, your supply chain must operate as a true strategic capability.”

Dr. Abdelaziz Toumi, Chief Executive Officer, Lupin Manufacturing Solutions, said, “We are delighted to announce our strategic alliance with PolyPeptide. As peptide-based therapies continue to transform the treatment landscape for metabolic and other chronic conditions, LMS is committed to ensuring reliable access to specialised materials that support large-scale commercial production. This underscores our mission to establish secure, agile, and future-ready supply pathways for innovators worldwide.”

Contact

PolyPeptide Group AG      
Corporate Communications  
Lauren Starr     
mediateam@polypeptide.com    
T: +41 43 502 0580    

PolyPeptide Group AG
Investor Relations
Tim Brandl 
investorrelations@polypeptide.com 
T: +41 43 502 0580 
 

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange.

For more information, please visit polypeptide.com.

@PolyPeptide — follow us on LinkedIn

About Lupin Manufacturing Solutions Limited (LMS)

Lupin Manufacturing Solutions Limited, a 100% subsidiary of Lupin Limited, is a leading manufacturer of Active Pharmaceutical Ingredients (APIs) and a global Contract Development and Manufacturing Organization (CDMO) offering standalone & integrated solutions across drug substances, complex chemistry, drug product, and advanced modalities, including ADCs and peptides. Leveraging Lupin’s legacy of scientific rigor and regulatory expertise, LMS supports biopharma innovators from early development to commercial scale. With state-of-the-art facilities, a client-first approach, and a team of 250+ scientists, LMS accelerates the path to market for transformative therapies.

For more details, visit https://www.lupin.com/LMS/  or email at lmsinfo@lupin.com

Disclaimer

This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise.